Please login to the form below

Not currently logged in
Email:
Password:

ALK inhibitor

This page shows the latest ALK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s flat sales focus investor attention on M&A

Pfizer’s flat sales focus investor attention on M&A

Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

Latest news

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    Pfizer files third-gen ALK inhibitor for lung cancer. The US FDA is set to make a decision on lorlatinib later this year. ... Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as

  • Novartis gets first-line approval for Xalkori challenger in EU Novartis gets first-line approval for Xalkori challenger in EU

    Novartis' Zykadia can now compete head-to-head in Europe against Pfizer's Xalkori after winning approval as a first-line therapy for ALK-positive non-small cell lung cancer (NSCLC). ... It is only the second ALK inhibitor approved for first-line use in

  • Novartis' Zykadia claims US approval for first-line lung cancer Novartis' Zykadia claims US approval for first-line lung cancer

    The approval is good news for Novartis, although its key competitor in the coming period will not be so much Xalkori as Roche's ALK inhibitor Alecensa (alectinib), which bested ... Meanwhile additional competition in the ALK inhibitor market is looming

  • Novartis' Zykadia prepped to take on Xalkori in Europe Novartis' Zykadia prepped to take on Xalkori in Europe

    More patients in Europe should be eligible for treatment with Novartis' Zykadia after the EMA's advisory committee backed first-line use of the ALK inhibitor. ... Previously Zykadia was only approved for use in ALK-positive NSCLC patients whose disease

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics